Oragenics COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action

Oragenics Inc OGEN announced the results from its hamster challenge study to evaluate the COVID-19 vaccine candidate.

• The study is assessing the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate.
• The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.
• Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. 
• By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. 
• Related: Oragenics Launches Animal Study For COVID-19 Vaccine Candidate.
• The Company plans to file Investigational New Drug Application to the FDA in Q2 of 2022.
• Price Action: OGEN shares are down 0.45% at $0.57 during the market session on the last check Wednesday.